|Videos|February 23, 2022
- Vol 50 No 06
- Volume 50
- Issue 06
Urology Times 50 Innovations Series: Clean intermittent catheterization
Author(s)Urology Times staff
"Intermittent catheterization is an important concept in urology, and it has a long history," says John Stoffel, MD.
Advertisement
In this installment of Urology Times®' 50th Anniversary Innovation Celebration series, John Stoffel, MD, discusses the development of clean intermittent catheterization and how it has improved the care of patients with urologic conditions. Stoffel is a Professor of Urology, and Chief of the Division Neurourology & Pelvic Reconstruction in the Department of Urology at the University of Michigan in Ann Arbor.
Articles in this issue
over 4 years ago
The role of mediation in medical malpractice litigationover 4 years ago
How do you bill for a 75-minute audio-only E/M visit?over 4 years ago
Telemedicine’s uncertain future in urologyover 4 years ago
Part D data reveal how urologists are prescribing antibioticsover 4 years ago
Same-side shock wave lithotripsy, URS present coding questionsover 4 years ago
What to consider when weighing pre-tax, Roth IRAsalmost 5 years ago
Dr. Amarasekera on supporting sexual minorities in healthcareAdvertisement
Related to this article
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Engy Habashy, MD, on the role of androgens in GSM management
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5